Nymox Announces First Patient Enrollment for NX02-0022 Reinjection Study of NX-1207 for BPH
April 23 2013 - 11:00AM
Nymox Pharmaceutical Corporation (Nasdaq:NYMX) is pleased to
announce that the first patient has been enrolled in the Company's
Study NX02-0022. The NX02-0022 Study is designed as an open label
study of the safety and efficacy of NX-1207 reinjection for the
treatment of prostate enlargement (benign prostatic hyperplasia or
BPH). The new study will enroll 100-200 subjects who had previously
participated in an NX-1207 BPH study and will involve a second
treatment of intraprostatic NX-1207 2.5 mg.
The new study will also use a lyophilized formulation of NX-1207
that can be stored at room temperature. The new formulation is also
being used in the Company's Phase 2 NX03-0040 prostate cancer study
which is in progress.
The use of NX-1207 for the treatment of moderate to severe BPH
is being evaluated in five Phase 3 trials. In addition to the large
U.S. pivotal Phase 3 studies (studies NX02-0017 and NX02-0018), the
new drug is being tested in two Phase 3 multi-center reinjection
studies (studies NX02-0020 and NX02-0022) and a multi-center Phase
3 study in Europe (in collaboration with Nymox's European partner,
Recordati S.p.A.). Two of these studies (NX02-0017 and NX02-0020)
have completed enrollment and a third (NX02-0018) is nearing
completion.
NX-1207 is also being evaluated in a U.S. Phase 2 study
(NX03-0040) for the treatment of localized low-risk prostate
cancer.
NX-1207 is a novel patented drug developed by Nymox. NX-1207 is
injected by a urologist under ultrasound guidance directly into the
area of the prostate to be treated in an in-clinic procedure that
takes only a few minutes and does not require catheterization,
anesthetics or sedation. Studies to date have shown that
intraprostatic NX-1207 treatment is well-tolerated by patients,
does not impair sexual function, and has not shown any drug-related
significant side effects.
In completed blinded multi-center U.S. clinical trials of
NX-1207 for the treatment of BPH, a single injection of NX-1207 has
been found to produce on average symptomatic improvements about
double that reported for currently approved BPH drugs without
causing the sexual or cardiovascular side effects associated with
those drugs. Follow-up studies have shown evidence of long lasting
benefit with a significant proportion of men who received a single
dose reporting maintained improvement in BPH symptoms without other
treatments for up to 7½ years.
More information about Nymox is available at www.nymox.com,
email: info@nymox.com, or 800-936-9669.
This press release contains certain "forward-looking statements"
as defined in the United States Private Securities Litigation
Reform Act of 1995 that involve a number of risks and
uncertainties. There can be no assurance that such statements will
prove to be accurate and the actual results and future events could
differ materially from management's current expectations. Such
factors are detailed from time to time in Nymox's filings with the
United States Securities and Exchange Commission and other
regulatory authorities.
CONTACT: Brian Doyle
Nymox Pharmaceutical Corporation
1-800-93NYMOX
www.nymox.com
Nymox Pharmaceutical (NASDAQ:NYMX)
Historical Stock Chart
From Apr 2024 to May 2024
Nymox Pharmaceutical (NASDAQ:NYMX)
Historical Stock Chart
From May 2023 to May 2024